中文

英搏尔 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-15
ItemAmountY/Y
Revenue¥1.09B+99.2%
Gross profit¥0.19B
Operating income¥0.06B
Net income¥0.06B+430.7%
Gross margin17.3%Net margin 5.2%
Revenue Q/Q-28.3%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.90B82.7%
R&D¥0.08B7.4%
SG&A¥0.04B3.9%
Tax & other¥-0.00B-0.0%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

朗新科技海特生物中石科技艾德生物智动力赛意信息创业黑马澄天伟业双一科技联合光电中赋科技盛弘股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies